Absorption and conjugation of metyrapone during diphenylhydantoin therapy: mechanism of the abnormal response to oral metyrapone.
D015065:17-Hydroxycorticosteroids / Q000097:blood / Q000652:urine; D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D000818:Animals; D001711:Biotransformation; D004790:Enzyme Induction; D007408:Intestinal Absorption; D008099:Liver / Q000166:cytology / Q000201:enzymology / Q000378:metabolism*; D008297:Male; D008797:Metyrapone / Q000097:blood / Q000378:metabolism*; D008854:Microscopy, Electron; D008861:Microsomes / Q000201:enzymology; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors; D010672:Phenytoin / Q000627:therapeutic use*; D011169:Portal Vein; D051381:Rats; D014683:Vena Cava, Superior
D015065:17-Hydroxycorticosteroids; D010672:Phenytoin; D000324:Adrenocorticotropic Hormone; D006899:Mixed Function Oxygenases; D008797:Metyrapone